Impaired glymphatic function and clearance of tau in an Alzheimer’s disease model

Author:

Harrison Ian F1ORCID,Ismail Ozama1,Machhada Asif12,Colgan Niall13,Ohene Yolanda1,Nahavandi Payam1,Ahmed Zeshan4,Fisher Alice4,Meftah Soraya4ORCID,Murray Tracey K4,Ottersen Ole P5,Nagelhus Erlend A6,O’Neill Michael J4,Wells Jack A1,Lythgoe Mark F1

Affiliation:

1. UCL Centre for Advanced Biomedical Imaging, Department of Imaging, Division of Medicine, University College London, London, UK

2. Department of Neuroscience, Physiology and Pharmacology, University College London, London, UK

3. School of Physics, National University of Ireland Galway, Ireland

4. Eli Lilly and Company, Erl Wood Manor, Windlesham, Surrey, UK

5. Office of the President, Karolinska Institutet, Stockholm, Sweden

6. Institute of Basic Medical Sciences, University of Oslo, Oslo, Norway

Abstract

Abstract The glymphatic system, that is aquaporin 4 (AQP4) facilitated exchange of CSF with interstitial fluid (ISF), may provide a clearance pathway for protein species such as amyloid-β and tau, which accumulate in the brain in Alzheimer’s disease. Further, tau protein transference via the extracellular space, the compartment that is cleared by the glymphatic pathway, allows for its neuron-to-neuron propagation, and the regional progression of tauopathy in the disorder. The glymphatic system therefore represents an exciting new target for Alzheimer’s disease. Here we aim to understand the involvement of glymphatic CSF-ISF exchange in tau pathology. First, we demonstrate impaired CSF-ISF exchange and AQP4 polarization in a mouse model of tauopathy, suggesting that this clearance pathway may have the potential to exacerbate or even induce pathogenic accumulation of tau. Subsequently, we establish the central role of AQP4 in the glymphatic clearance of tau from the brain; showing marked impaired glymphatic CSF-ISF exchange and tau protein clearance using the novel AQP4 inhibitor, TGN-020. As such, we show that this system presents as a novel druggable target for the treatment of Alzheimer’s disease, and possibly other neurodegenerative diseases alike.

Funder

Eli Lilly and Company

Engineering and Physical Sciences Research Council

EPSRC

Alzheimer’s Research UK

Parkinson’s UK

Wellcome Trust

Royal Society Sir Henry Dale Fellowship

King’s College London

UCL Comprehensive Cancer Imaging Centre

Regenerative Medicine Platform Safety Hub

Publisher

Oxford University Press (OUP)

Subject

Neurology (clinical)

Cited by 298 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3